[ad_1]
HANGZHOU, China and SHAOXING, China, March 27, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX:1672) today announces that the latest preclinical research results of the company’s two novel anti-cancer drug candidates, ASC61, an oral PD-L1 inhibitor and ASC60, an oral fatty acid synthase (FASN) inhibitor have been selected for presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022 (the “2022 AACR Annual Meeting“), and the abstracts have already been published on AACR’s official website.
The AACR annual meeting is one of the world’s largest and long-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. The AACR annual meeting for this year will be held in New Orleans, Louisiana on April 8 to 13, 2022 CDT.
The abstracts selected for poster presentations at the 2022 AACR Annual Meeting are as follows:
（1） ASC61
Abstract Title: In vivo efficacy evaluation of ASC61, an oral PD-L1 inhibitor, in two tumor mouse models
- Presentation Type: Poster Presentation
- Abstract Number: 5529
- Session Category: Immunology
- Session Title: Preclinical Immunotherapy
- Presentation time: April 8, 2022, 12:00PM – 1:00 PM CDT
- Presenter/Authors: Jinzi J. Wu, Handan He. Ascletis BioScience Co., Ltd.
ASC61 is an oral potent and highly selective PD-L1 small molecule inhibitor and blocks PD-1/PD-L1 interaction through inducing PD-L1 dimerization and internalization. Preclinical studies showed that ASC61 demonstrated significant antitumor efficacies and were well-tolerated in both syngeneic and humanized tumor mouse models. ASC61 was found to have favorably comparable antitumor activities as the U.S. Food and Drug Administration (FDA) approved PD-L1 therapeutic monoclonal antibody (mAb), Atezolizumab. The Phase I study of ASC61 in advanced solid tumors has received the…
[ad_2]
